Table 1.
Baseline characteristics stratified by baseline urinary albumin-creatinine ratio
| Characteristic | Normoalbuminuria, n=2553 | Microalbuminuria, n=778 | Macroalbuminuria, n=201 |
|---|---|---|---|
| End point | |||
| Kidney outcome | 51 | 45 | 41 |
| Baseline characteristics | |||
| Age, yr | 63 (8) | 63 (8) | 63 (7) |
| Sex, n (%) | |||
| Men | 1660 (65) | 564 (72) | 143 (71) |
| Women | 893 (35) | 214 (28) | 58 (29) |
| Race, n (%) | |||
| Asian | 243 (10) | 92 (12) | 18 (9) |
| Black | 54 (2) | 18 (2) | 9 (4) |
| White | 2085 (82) | 624 (80) | 163 (81) |
| Other | 171 (7) | 44 (6) | 11 (5) |
| BMI, kg/m2a | 32.6 (6.2) | 32.9 (6.1) | 32.4 (5.8) |
| Cardiovascular disease history, n (%) | 1511 (59) | 470 (60) | 120 (60) |
| Systolic BP, mm Hg | 135 (15) | 139 (16) | 146 (18) |
| Diastolic BP, mm Hg | 77 (10) | 78 (10) | 80 (10) |
| LDL cholesterol, mg/dla | 88 (35) | 86 (35) | 97 (40) |
| HbA1c, % | 8.1 (0.9) | 8.3 (0.9) | 8.4 (0.9) |
| eGFR, ml/min per 1.73 m2a | 80 (17) | 78 (18) | 70 (21) |
| UACR, mg/g | 8.2 (5.5–13.2) | 66.8 (43.6–121.4) | 675.4 (436.8–1167.1) |
| TNFR-1, pg/ml | 2477 (2068–2990) | 2781.5 (2290–3484) | 3495 (2792–4414) |
| TNFR-2, pg/ml | 9323 (7642–11,392) | 10,475 (8403–13,185) | 12,834 (10,338–17,459) |
| KIM-1, pg/ml | 97 (64–145) | 143.5 (98–225) | 281 (186–474) |
| Treatment allocation, n (%) | |||
| Placebo | 847 (33) | 257 (33) | 81 (40) |
| Canagliflozin | 1706 (67) | 521 (67) | 120 (60) |
Data are n (percentage), mean (SD), or median (25th to 75th percentiles). BMI, body mass index; HbA1c, glycated hemoglobin; UACR, urinary albumin-creatinine ratio; TNFR-1, TNF receptor-1; TNFR-2, TNF receptor-2; KIM-1, kidney injury molecule-1.
a
Mean BMI (four patients), LDL cholesterol (three patients), and creatinine (two patients) values were imputed for patients with missing baseline values.